Award
National Cancer Institute 5R01CA286918-02
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate
Recipient
National Cancer Institute (NCI), part of the NIH, United States
Award Amount
$715,058.00
Ceiling
$715,058.00
Awarded
June 24, 2025
Identifier
5R01CA286918-02
Award for research on DLL3-targeted agents for diagnosis and therapy of high-grade neuroendocrine carcinomas, funded by NIH/NCI.
Description
The project involves evaluating DLL3-targeted radiolabeled monoclonal antibodies for diagnosis and therapy of high-grade neuroendocrine carcinomas. The study includes PET imaging and radiolabeled antibody therapy. The project is funded by the NIH/NCI with a focus on innovative theranostic approaches.